Image

Resolution: Support for Legislation that Promotes the Production of New Antimicrobial Drugs

Access the Recommendation Report

Resolution: Support for Legislation that Promotes the Production of New Antimicrobial Drugs - PDF*

Executive Summary

We continue to face a critical deficit in our battle against AMR – a severe lack of new antimicrobial drugs. Private industry is no longer sufficiently investing in developing new antimicrobial drugs because the costs of drug development far outpace the revenues companies can receive from sales, and several small companies with newly FDA-approved antimicrobial drugs have filed for bankruptcy. This resolution letter expresses PACCARB’s support for legislation that will spur and sustain investment in the pipeline of new antimicrobial drugs while still encouraging appropriate stewardship practices, such as the DISARM and PASTEUR Acts.

Associated PACCARB Working Group

This report was compiled by the Immediate Action Working Group, and was voted on and approved by the full council at the 18th PACCARB Public Meeting on October 6, 2021. This working group was established to provide recommendations addressing topics of immediate concern related to antimicrobial resistance.

*People using assistive technology may not be able to fully access information in these files. For assistance, contact the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria by emailing CARB@hhs.gov.

Content created by Assistant Secretary for Health (ASH)
Content last reviewed August 31, 2023